文献速递乳房整形与再造显微修复重建

激素治疗是否增加腹部显微外科乳房再造的围手术期并发症?

Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?
PubMed 文献 · Plast Reconstr Surg · 2018-01-01

回顾性分析2004至2015年某学术机构853例(1253个皮瓣)腹部显微外科乳房再造患者,193例(269个皮瓣)接受激素治疗,660例(984个皮瓣)未接受。激素治疗组与非治疗组完全皮瓣丢失率(1.0% vs 1.1%)和部分皮瓣丢失率(2.2% vs 1.5%)无统计学显著差异。高血压和既往乳房手术是轻微并发症和总体并发症的唯一独立危险因素。

要点

  • 激素治疗组与非治疗组完全皮瓣丢失率(1.0% vs 1.1%)无统计学显著差异。
  • 激素治疗组与非治疗组部分皮瓣丢失率(2.2% vs 1.5%)无统计学显著差异。
  • 高血压和既往乳房手术是轻微及总体并发症的独立危险因素。

核心结论

  • 激素治疗与完全或部分皮瓣丢失或总体并发症发生率升高无关。
  • 作者提出对术前停用他莫昔芬或芳香化酶抑制剂采取个体化方法。

研究设计与样本

  • 回顾性综述,纳入2004至2015年某学术机构接受腹部显微外科乳房再造的患者。
  • 共853例患者(1253个皮瓣),其中193例(269个皮瓣)手术时接受激素治疗,660例(984个皮瓣)未接受。
  • 比较并发症发生率,包括完全或部分皮瓣丢失及总体并发症,采用单因素和逻辑回归模型分析。

主要发现

  • 激素治疗组与非治疗组完全皮瓣丢失率分别为1.0%和1.1%,无统计学显著差异。
  • 激素治疗组与非治疗组部分皮瓣丢失率分别为2.2%和1.5%,无统计学显著差异。
  • 高血压是轻微并发症的独立危险因素(调整OR 2.1;95%CI 1.3至3.6;p=0.005),也是总体并发症的独立危险因素(调整OR 2.2;95%CI 1.3至3.7;p=0.004)。
  • 既往乳房手术是轻微并发症的独立危险因素(调整OR 1.8;95%CI 1.2至2.7;p=0.009),也是总体并发症的独立危险因素(调整OR 1.9;95%CI 1.3至3.0;p=0.003)。
  • 激素治疗组较非治疗组有更高的既往乳房手术率、晚期癌症分期、再造前化放疗率以及延期和单侧再造率。

临床怎么用

  • 作者提出对术前停用他莫昔芬或芳香化酶抑制剂采取个体化方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of hormone therapy (tamoxifen and aromatase inhibitors) has been shown to increase venous thromboembolism. As breast cancer patients undergoing microsurgical breast reconstruction are often receiving hormone therapy, it is unclear whether this increased thrombotic risk is associated with increased flap loss. METHODS: A retrospective review was performed on patients undergoing abdominally based microsurgical breast reconstruction at an academic institution from 2004 to 2015. Patients were divided by use of hormone therapy at the time of surgery. Complication rates, including complete or partial flap loss and overall complications, were compared and analyzed using univariate and logistic regression models. RESULTS: Among a total of 853 patients (1253 flaps), 193 patients (269 flaps) were receiving hormone therapy and 660 patients (984 flaps) were not. Patients on hormone therapy had higher rates of previous breast surgery, advanced cancer stage, chemoradiation before reconstruction, and delayed and unilateral reconstruction. There were no statistically significant differences between hormone therapy patients and nontherapy patients in complete flap loss (1.0 percent versus 1.1 percent) and partial flap loss (2.2 percent versus 1.5 percent). Hypertension and previous breast surgery were the only independent risk factors for minor complications (adjusted OR, 2.1; 95 percent CI, 1.3 to 3.6; p = 0.005; and adjusted OR, 1.8; 95 percent CI, 1.2 to 2.7; p = 0.009, respectively) and overall complications (adjusted OR, 2.2; 95 percent CI, 1.3 to 3.7; p = 0.004; and adjusted OR, 1.9; 95 percent CI, 1.3 to 3.0; p = 0.003, respectively). CONCLUSIONS: Hormone therapy was not associated with a higher incidence of complete or partial flap loss or overall complications. The authors propose an individualized approach to the preoperative cessation of tamoxifen or aromatase inhibitors. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Tran BNN, Ruan QZ, Cohen JB, et al. Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction? Plast Reconstr Surg. 2018. PMID: 29794694. doi:10.1097/PRS.0000000000004359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。